LSE Healthcare Biotechnology 0EE0.L

uniQure N.V.

$ 47.01 -1.43 %

uniQure N.V. is a pioneering gene therapy company dedicated to discovering and developing therapeutic solutions for individuals afflicted with severe genetic and other debilitating illnesses. Its flagship program, Etranacogene dezaparvovec (AMT-061), is currently in a pivotal Phase III HOPE-B clinical trial for treating hemophilia B. The company's robust pipeline extends to several other promising candidates, including AMT-130, a gene therapy undergoing Phase I/II studies for Huntington's disease, and AMT-060, also in Phase I/II for hemophilia B. Additionally, uniQure is advancing product candidates such as AMT-210 for Parkinson's disease, AMT-260 for temporal lobe epilepsy, the preclinical AMT-240 for autosomal dominant Alzheimer's disease, and AMT-161 for amyotrophic lateral sclerosis. Founded in 1998, uniQure N.V. is headquartered in Amsterdam, the Netherlands.

CEO: Matthew Craig Kapusta - https://www.uniqure.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

Buy

DCF

$ -8.16

Loading data...

0EE0.L vs S&P500

Loading data...

No data available.

Quick ratio

10.40

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

6.83

may indicate that the company is undervalued or has poor growth prospects.

EPS

6.89

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-145.81 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-26.48 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

9.38

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.42

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

-2.74

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
2 indicates worrying financial health
Altman score
0.33 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
2.36 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.08 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.